23
Participants
Start Date
December 20, 2011
Primary Completion Date
May 14, 2013
Study Completion Date
May 14, 2013
BAX326
All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50 exposure days, whichever occurred last.
S.C. Sanador SRL, Bucharest
"State Institution Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine", Lviv
LNJP Maulana Azad Medical College & Associated Hospitals, New Delhi
Republican Center for Hemophilia Treatment, Saint Petersburg
Louis Turcanu Emergency Children's Hospital, Timișoara
Pediatric Regional Clinical Hospital, Hematology Department, Krasnodar
Regional Clinical Hospital, Yekaterinburg
University Pediatric Hospital, Krakow
Stanislaw Popowski Provincial Specialist Pediatric Hospital, Olsztyn
Professor Tadeusz Sokolowski Independent Public Teaching Hospital of the Pomeranian Medical University in Szczecin, Szczecin
Manchester Children´s Hospital, Manchester
Baxalta now part of Shire
INDUSTRY